EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quantitative high-throughput screening identifies small-molecule modulators of Wnt/β-catenin signaling

Xing Chen, Shu Yang, Srilatha Sakamuru, Chainarong Sukhawanit, Savannah Wood, Masato Ooka, Ruili Huang, Menghang Xia

Frontiers in Pharmacology · 02.04.2026 · 17

DOI: 10.3389/fphar.2026.1788041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 02.04.2026. Verfasst von Xing Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD,…. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Wnt/β-catenin signaling pathway plays an important role in development and tissue homeostasis, and its dysregulation is implicated in various pathologies, including cancer, fibrosis, and neurodegeneration. However, the discovery of small-molecule modulators of this pathway remains challenging due to the pathway’s inherent complexity, characterized by ligand redundancy, overlapping receptor usage, and compensatory downstream signaling. In this study, we optimized a cell-based LEF/TCF-β-lactamase reporter assay for quantitative high-throughput screening in a 1536-well format. Screening 1280 compounds from the Library of Pharmacologically Active Compounds alongside 88 compounds from the Tox21 collection identified twelve potential antagonists of Wnt/β-catenin signaling. Follow-up studies confirmed the activity of 10 compounds, demonstrating consistent activity across two independent reporter systems (β-lactamase and luciferase). Western blot analysis showed that all compounds except for cytosine-1-beta-D-arabinofuranoside and PMEG reduced accumulation of both non-phosphorylated β-catenin (active) and total β-catenin, providing orthogonal validation of pathway inhibition. The identification of known Wnt inhibitors such as emetine, tyrphostin A9, niclosamide, ouabain, and podophyllotoxin further validated the assay’s robustness. Collectively, this study establishes a robust 1536-well screening platform for identifying Wnt pathway modulators and identifies topotecan, amsacrine, brefeldin A, and tyrphostin AG 879 as candidate small-molecule antagonist, thereby expanding the chemical tools for investigating Wnt/β-catenin signaling.

Schlagwörter

Stichwörter der Autor:innen

Wnt signalingbrefeldin Ahigh-throughput screeninginhibitorβ-catenin

Autor:innen und Institutionen

  • Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, United States.

Zitieren

APA

Chen, X., Yang, S., Sakamuru, S., Sukhawanit, C., Wood, S., Ooka, M., Huang, R., & Xia, M. (2026). Quantitative high-throughput screening identifies small-molecule modulators of Wnt/β-catenin signaling. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1788041

Vancouver

Chen X, Yang S, Sakamuru S, Sukhawanit C, Wood S, Ooka M, et al. Quantitative high-throughput screening identifies small-molecule modulators of Wnt/β-catenin signaling. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1788041

BibTeX
@article{Chen2026,
  author = {Chen, Xing and Yang, Shu and Sakamuru, Srilatha and Sukhawanit, Chainarong and Wood, Savannah and Ooka, Masato and Huang, Ruili and Xia, Menghang},
  title = {Quantitative high-throughput screening identifies small-molecule modulators of Wnt/β-catenin signaling},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1788041}
}
Kostenlos starten →